B-cell translocation gene 2 (BTG2)

B-cell translocation gene 2 (BTG2) is a member of the BTG/Tob family of antiproliferative proteins that acts as a transcriptional co-regulator and is involved in multiple biological processes including cell cycle regulation, proliferation, apoptosis, differentiation, and DNA damage response. BTG2 is highly expressed in various tissues including the pancreas, thymus, CNS, and immune system, and functions predominantly as a tumor suppressor by promoting cell cycle arrest (notably at the G1/S and G2/M transitions), enhancing apoptosis, and facilitating DNA damage repair (often via p53-dependent pathways)[1][2][3][4]. At the molecular level, BTG2 interacts with the CCR4-NOT complex and PRMT1, enhancing mRNA deadenylation and global mRNA decay, thereby reducing cellular transcript stability and protein synthesis, particularly in quiescent or differentiating cells[3][5]. While BTG2 overexpression is generally associated with tumor suppression, in some contexts (e.g., certain bladder cancers) it may promote migration, suggesting tissue- or cancer type-specific effects. BTG2 is under active investigation as a biomarker for cancer diagnosis and prognosis but, to date, is not the direct target of approved drugs[1][3].

Other names

Protein BTG2NGF-inducible anti-proliferative protein PC3TIS21PC3APRO1BTG family member 2NGF-inducible protein TIS21B-cell translocation gene 2Pheochromocytoma cell-3

Not applicable for current therapeutics; BTG2 acts as a tumor suppressor and transcription co-regulator—theoretical mechanisms would include altering BTG2 levels to restore cell cycle arrest, promote apoptosis, or increase DNA repair in cancer.